H epatocellular carcinoma (HCC) staging guides patient prognosis and treatment allocation; however, there is no universally accepted staging system for HCC. The most widely endorsed staging system is the Barcelona Clinic Liver Cancer (BCLC) system, which incorporates tumor burden, functional status, and liver function.
H epatocellular carcinoma (HCC) staging guides patient prognosis and treatment allocation; however, there is no universally accepted staging system for HCC. The most widely endorsed staging system is the Barcelona Clinic Liver Cancer (BCLC) system, which incorporates tumor burden, functional status, and liver function. 1 We aimed to compare the discriminant ability of several staging systems for HCC in a geographically diverse multicenter US cohort.
Methods
We conducted a retrospective cohort study of patients newly diagnosed with HCC at 4 US health systems between June 1, 2012, and May 31, 2013.
Patients were identified by International Classification of Diseases, 9th revision, codes for HCC (155.0 or 155.2), tumor conference lists, and prospectively maintained databases. We adjudicated HCC cases to confirm they met diagnostic criteria, based on published criteria. 2 We excluded patients with missing data for any of the included staging systems.
Patient clinical course, including dates of treatment, follow-up imaging, and death, was recorded at each site. Outcomes were recorded from the clinical notes, and in the case of death, all attempts were made to verify the date of death including a search of local obituary listings. Patients were followed up from enrollment to death, referral to hospice care, or the end of the follow-up period. This study was approved by the Institutional Review Boards at each study site.
Statistical Analysis
We assessed the prognostic performance of each system (the Italian Liver Cancer, Hong Kong Liver Cancer [HKLC], Cancer of the Liver Italian Program, and the model to estimate survival in ambulatory patients with hepatocellular carcinoma [MESIAH] systems [3] [4] [5] [6] ) based on the Akaike information criterion (AIC), 7 the discriminatory ability linear trend chi-square, 8 and the concordance index (C-index). 9 We calculated the AIC and the linear trend chi-square based on separate Cox models for each staging system. We resampled the data set with replacement (bootstrap) 1000 times to calculate an empiric distribution for the C-index and the difference between C-indices for each staging system and pair of staging systems. We then used these empiric distributions to estimate a central 95% CI for each C-index and the difference between C-indices. All analyses were completed in SAS v 9.3 (SAS Institute, Cary, NC).
Results
In total, 320 patients met inclusion criteria. Baseline characteristics were notable for being predominantly male (75.3%), white (48.8%), and had a mean age of 61.0 AE 9.4 years. The most common liver disease etiology was hepatitis C (48.8%), and the majority of patients had Child-Turcotte-Pugh (CTP) class A liver disease (49.4%; CTP class B, 33.7%; and CTP class C, 16.9%). The median Eastern Cooperative Oncology Group score was 1 (interquartile range [IQR], 0-1). The median number of tumors was 1 (IQR, 1-3) , and the median tumor diameter was 3.8 cm (IQR, 2.2-7.5 cm). Vascular invasion and metastases were present in 22.5% and 8.1%, respectively. The mean follow-up period was 382 AE 302 days, and the 1-year survival rate was 58.8%.
The MESIAH system had the lowest AIC and the highest discriminatory ability linear trend chi-square, whereas the HKLC showed the highest C-index at 0.769. Notably, the BCLC system had the worst discriminant ability in all measures, including the highest AIC, lowest discriminatory ability linear trend chi-square, and lowest C-statistic. The Cancer of the Liver Italian Program and the Italian Liver Cancer systems were intermediate in their discriminant ability.
Bootstrapped comparison of the C-indices of the staging systems is shown in Table 1 . Although no staging system showed superiority over the others, both the HKLC and MESIAH had significantly higher C-indices than the BCLC (P ¼ .004 and .026, respectively).
Discussion
Accurate staging is central to prognosticating and allocating treatment in patients with HCC. We report the comparative ability of several HCC staging systems in a multicenter, geographically and demographically diverse cohort in the United States. We found that the HKLC and MESIAH staging systems outperformed the BCLC in discriminant ability.
Our study had some notable strengths and weaknesses. First, we captured receipt of all HCC treatments at our institutions, however, there could be ascertainment bias for medical care received at outside institutions. In addition, our study was conducted at 4 academic centers and our results may not be generalized to all practice settings.
In conclusion, we have shown that the HKLC and MESIAH staging systems are superior to the widely accepted BCLC in a multicenter US cohort. Notably, the maximum C-index in our cohort was 0.769, which is in the very good range. To improve on this, future staging systems may rely on features such as imaging characteristics or tumor genetic alterations, rather than solely on laboratory and patient-level variables. While better systems are being developed, we have shown that some of the more contemporary systems for HCC staging deserve stronger consideration for more widespread adoption. 
